Efficacious Anti-Cancer Drugs Targeting Nicotinamide N-Methyltransferase (NNMT) in Cultured Human Oral Squamous Cell Carcinoma (OSCC)

Read full text
Authors: Brian P. Maloney, Martyna Kubisztal, Ziqian Ge, Yin Lu, Lisa Strotmann, Adrianna Budzinska, Mary Francis Rooney, Marilena Karavyraki, Andrew J. S. Knox, Richard K. Porter
Cited by: 1

Abstract

Oral squamous cell carcinoma (OSCC) is major cause of human cancer. The enzyme, nicotinamide N-methyltransferase (NNMT) is overexpressed in a variety of human cancers including OSCC. Our laboratory identified two small molecule inhibitors of NNMT (AG-670 and AO-022) based on a pharmacophore of the in silico nicotinamide binding site. These inhibitors were demonstrated to inhibit the isolated NNMT enzyme with EC50 values in the micromolar range. Using an oral squamous cancer cell line as a model, it was demonstrated that NNMT is expressed in SCC-4 cells, but not MCF 7 cells, and that the inhibitors were cytotoxic to SCC-4 cells (IC50 values in the micromolar range). In an endeavour to investigate the mechanism behind their lethality, sub-lethal doses of the inhibitors were demonstrated to inhibit in situ mitochondrial oxygen consumption in SCC-4 cells but not in MCF 7 cells. It was further demonstrated that the NNMT inhibitors did not directly inhibit mitochondrial electron transport chain activity. Thus, we can deduce that the NNMT inhibitors effect mitochondrial activity indirectly via NNMT. We conclude that NNMT is a potential drug target for oral cancer.

Fields of Study & Subjects

Sirtuins and Resveratrol in Medicine Biochemical and Molecular Research PARP inhibition in cancer therapy

Publication details

Journal / source
Preprints.org
Publisher
MDPI AG
Publication date
13 February 2026
Document type
Preprint